Evolva stands for a world where there is less sugar in your food, you and your family are safe from biting ticks, and your cat lives longer—and that’s just for starters.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More

Cell and Gene Therapy, Industrial Impact

AXCELLA ANNOUNCES FDA IND CLEARANCE FOR AXA1125

Axcella | February 16, 2023

news image

On February 15, 2023, Axcella Therapeutics, a clinical-stage biotechnology firm that develops innovative approaches to complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the United States for AXA1125 for the treatment of Long COVID Fatigue. The company stated that it has obtained FDA regulato...

Read More

ANGSTROM BIO LAUNCHES AMPD™, PLATFORM FOR HIGH-ACCURACY, HIGH-FREQUENCY, LOW-COST COVID-19 AND RESPIRATORY PATHOGEN TESTING

Angstrom Bio | October 14, 2020

news image

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

Read More

MEDICINAL GENOMICS ANNOUNCES NEW PATHOSEEK® ASPERGILLUS MULTIPLEX ASSAY TO STREAMLINE CANNABIS TESTING

BioSpace | February 27, 2020

news image

Medicinal Genomics (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus— A. flavus, A. fumigatus, A. niger, and A. terreus — on cannabis samples using just one qPCR reaction. This new Aspergillus assay is the first and only qPCR multiplex that can satisfy the Californ...

Read More
news image

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More
news image

Cell and Gene Therapy, Industrial Impact

AXCELLA ANNOUNCES FDA IND CLEARANCE FOR AXA1125

Axcella | February 16, 2023

On February 15, 2023, Axcella Therapeutics, a clinical-stage biotechnology firm that develops innovative approaches to complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the United States for AXA1125 for the treatment of Long COVID Fatigue. The company stated that it has obtained FDA regulato...

Read More
news image

ANGSTROM BIO LAUNCHES AMPD™, PLATFORM FOR HIGH-ACCURACY, HIGH-FREQUENCY, LOW-COST COVID-19 AND RESPIRATORY PATHOGEN TESTING

Angstrom Bio | October 14, 2020

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

Read More
news image

MEDICINAL GENOMICS ANNOUNCES NEW PATHOSEEK® ASPERGILLUS MULTIPLEX ASSAY TO STREAMLINE CANNABIS TESTING

BioSpace | February 27, 2020

Medicinal Genomics (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus— A. flavus, A. fumigatus, A. niger, and A. terreus — on cannabis samples using just one qPCR reaction. This new Aspergillus assay is the first and only qPCR multiplex that can satisfy the Californ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us